PATENT CLAIM ANALYSIS

Application Number: 15870308
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "04400A"]

Abstract:
The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

Claim (Index 22):
A method of treating muscular dystrophy, comprising administering to a patient in need thereof a therapeutically effective amount of pharmaceutical composition of  claim 20 .

Metadata:
- Claim Count in Document: 33.0
- Percentile: 86.0
- Lexical Diversity: 1.75758
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14368307', '15339069', '13819520', '15619996', '14615504']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8921552060858637
- 35 USC 102 Novelty (BERT): 0.669204591214266
- Combined Prediction Score: 0.869860144598704
- Mean Citation Score: 750.7423379999999
- Max Citation Score: 937.6796
- Similarity Product: 639.5946625757217

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test